Generic Times Product News

MARCH 01, 2007

Morphine Sulfate Concentrated Oral Solution InveAmp Ampoules

Marketed by: ETHEX Corp (St. Louis, Mo)

Compared to: Roxanol (Xanodyne) and MSIR Oral Solution Concentrate (Purdue Frederick)

Indication: ETHEX recently introduced 2 new dosages—10 mg/0.5 mL and 5 mg/0.25 mL—of Morphine Sulfate immediate-release Concentrated Oral Solution InveAmp Ampoules. The product is indicated for the relief of severe acute and chronic pain. Each InveAmp ampoule is individually wrapped in a foil pouch for ease of identification. Also, each foil pouch is bar-coded to help improve dispensing accuracy and reverse-numbered to enhance inventory control.

Dosage Form: Ampoules: 5 mg/0.25 mL; 10 mg/0.5 mL; 20 mg/1 mL

For More Information:

Sertraline Hydrochloride Tablets, 25, 50, and 100 mg

Marketed by: Roxane Laboratories Inc (Columbus, Ohio), a subsidiary of Boehringer Ingelheim Corp

Compared to: Zoloft Tablets (Pfizer Inc)

Indication: February 6, 2007—Roxane Laboratories announced the launch of Sertraline Hydrochloride Tablets, 25, 50, and 100 mg. Sertraline hydrochloride is a selective serotonin reuptake inhibitor for oral administration. These tablets are indicated for the treatment of major depressive disorder in adults.

Dosage Form: Tablets: 25, 50, and 100 mg

For More Information: 800-962-8364

Simvastatin Tablets USP, 5, 10, 20, 40, and 80 mg

Marketed by: Perrigo Co (Allegan, Mich)

Compared to: Zocor Tablets (Merck & Co Inc)

Indication: December 19, 2006—The Perrigo Co announced that it received final approval from the FDA to market Simvastatin Tablets USP, 5, 10, 20, 40, and 80 mg. Perrigo's partner, Bentley Pharmaceuticals Inc, is manufacturing the product in Zaragoza, Spain. These tablets are a lipid-lowering agent and have several cardiovascular indications: for the treatment of patients with coronary heart disease (CHD) or at high risk of CHD or for reductions in risk of CHD mortality and cardiovascular events; patients with hypercholesterolemia requiring modifications of lipid profiles; and adolescent patients with heterozygous familial hypercholesterolemia.

Dosage Form: Tablets: 5, 10, 20, 40, and 80 mg

For More Information:

Sodium Sulfacetamide Lotion, 10%

Marketed by: Prasco Laboratories (Cincinnati, Ohio)

Compared to: Klaron (sanofi-aventis)

Indication: January 16, 2007—Prasco Laboratories began shipping Sodium Sulfacetamide Lotion 10%, the authorized generic of sanofiaventis' Klaron. Sodium Sulfacetamide Lotion 10% is AB-rated to Klaron and is indicated in the topical control of acne vulgaris. Each milliliter of Sodium Sulfacetamide Lotion 10% contains 100 mg of sodium sulfacetamide in a vehicle consisting of purified water; propylene glycol; lauramide DEA and diethanolamine; polyethylene glycol 400, monolaurate; hydroxyethyl cellulose; sodium chloride; sodium metabisulfite; methylparaben; xanthan gum; ethylenediaminetetraacetic acid; and simethicone.

Dosage Form: 118-mL bottle

For More Information: